Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.65 USD | -2.67% | -2.29% | +11.86% |
23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
23/04 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 1.43B | |
+3.15% | 108B | |
+11.10% | 104B | |
+1.28% | 22.33B | |
-12.75% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.75% | 17.64B | |
+4.20% | 14.05B | |
+34.79% | 12.51B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating